Summary & Overview
HCPCS Level II J0840: Crotalidae Polyvalent Immune Fab (Ovine), Injection
HCPCS Level II code J0840 denotes the injectable antivenom crotalidae polyvalent immune fab (ovine), billed per unit of up to 1 gram. Nationally, this code is used in acute clinical scenarios for the treatment of crotaline snake envenomation and is critical for timely, potentially life-saving care. Use of this product has implications for hospital formularies, emergency department supply management, and payer coverage policies due to its high cost and urgent clinical context.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical indication, typical sites of service, and where it fits in acute care delivery. The publication also summarizes payer coverage considerations and benchmarking where available, highlights common billing modifiers and documentation themes, and outlines policy and clinical context relevant to coding and reimbursement for antivenom administration.
This resource is intended for revenue cycle leaders, emergency medicine clinicians, pharmacy directors, and policy analysts seeking a focused briefing on HCPCS Level II code J0840, its clinical role, and the billing environment surrounding antivenom therapy.
Billing Code Overview
HCPCS Level II code J0840 represents the injection of crotalidae polyvalent immune fab (ovine), dosed up to 1 gram per billing unit. This product is an antivenom derived from ovine sources and is indicated for the treatment of envenomation by crotaline snakes (rattlesnakes, copperheads, cottonmouths) where antivenom therapy is clinically indicated.
-
Service type: Injectable biologic/antivenom therapy
-
Typical site of service: Acute care settings such as emergency departments, inpatient hospital units, and other facilities equipped to manage acute envenomation and potential infusion-related reactions
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to the emergency department or urgent care after a venomous pit viper (rattlesnake, copperhead, water moccasin) bite with local progressive swelling, ecchymosis, systemic signs (hypotension, coagulopathy, tachycardia), or laboratory evidence of envenomation (thrombocytopenia, prolonged coagulation studies, hemolysis). Initial evaluation includes airway/breathing/circulation stabilization, local wound care, tetanus status assessment, serial limb circumference measurements, and baseline laboratory tests (CBC, coagulation panel, fibrinogen, metabolic panel, type and screen). When clinical or laboratory indicators meet institutional antivenom criteria, the treating physician orders administration of crotalidae polyvalent immune fab (ovine) J0840. Dosing is weight-independent per vial counts; administration occurs intravenously via infusion, typically in the ED, observation unit, or inpatient setting, with continuous monitoring for hypersensitivity or serum sickness. Staff document indication, lot number, vials used, infusion start/stop times, premedication if given, and response to therapy. Follow-up includes serial labs, wound reassessment, and monitoring for recurrence of venom effects; patients may require additional vials based on clinical response or repeat labs. Typical sites of service: Emergency Department, Observation Unit, or Inpatient Hospital.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier |